Compare Nomura Holdings Inc (NMR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Summit Therapeutics Inc — how do they compare? Nomura Holdings Inc trades at $10.84 (market cap $31.31B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Nomura Holdings Inc is far larger — about 2.3× Summit Therapeutics Inc's market cap, and Nomura Holdings Inc pays a 3.05% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NMR | SMMT | |
|---|---|---|
Market Cap | $31.31B | $13.79B |
Sector | Financials | Health |
52-Week High | $10.65 | $26.38 |
52-Week Low | $6.73 | $12.43 |
Dividend Yield | 3.05% | — |
Enterprise Value | — | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $10.63, down 0.19% on the day, with a bullish technical signal driven by moving averages. Recent earnings show mixed quarterly performance but strong annual growth, with revenue reaching $1.66 trillion in 2025 and net income margin at 20.4%. The stock is supported by positive momentum coverage and a solid ROE of 11.03%.
Outlook remains favorable due to valuation metrics like a P/E of 12.46 and bullish analyst sentiment, though risks include volatile cash flows and rising debt-to-asset ratios. Investment opportunity lies in continued wholesale segment growth and ROE expansion, balanced by execution risks in a competitive financial sector.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
